Success Metrics

Active Trials

3(60%)

Phase Distribution

Ph early_phase_1

20%

Ph not_applicable

40%

Ph phase_1

20%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

1(20.0%)

N/ANon-phased studies

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Terminated(2)

Detailed Status

Withdrawn2

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (20.0%)

Phase 11 (20.0%)

Phase 21 (20.0%)

N/A2 (40.0%)

Trials by Status

withdrawn240%

recruiting240%

active_not_recruiting120%

Recent Activity

3 active trials

Showing 5 of 5

active_not_recruitingphase_2

Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study

NCT05128903

withdrawnphase_1

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

NCT05672082

Clinical Trials (5)

Showing 5 of 5 trials

NCT05128903Phase 2

Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study

Active Not Recruiting

NCT05238961Phase 1

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Withdrawn

NCT06453915Early Phase 1

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Recruiting

NCT05911178Not Applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Recruiting

NCT05672082Not Applicable

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5